# American Society of Clinical Oncology (ASCO) Annual Meeting 2019
Friday, May 31 – Tuesday, June 4
[https://am.asco.org/](https://am.asco.org/)

Cancer Center Members indicated in **BOLD**

## Presentations and Session Chairs

**Mikkael A. Sekeres, MD, MS**, Cleveland Clinic Taussig Cancer Institute
Interactive Case-Based Session: [Do We Know How to Use Hypomethylating Agents in Myeloid Disorders?](#)
Speaker, “What Is the Right Decitabine Treatment Duration?”
Friday, May 31, 2019, 1:00 PM - 2:00 PM, E451

**Nathan A. Pennell, MD, PhD**, Cleveland Clinic
Chair, Education Session: [Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?](#)
Speaker, “Guidelines, Barriers, Access to Molecular Testing in NSCLC”
Friday, May 31, 2019, 2:45 PM - 3:00 PM, Hall D1

Pradnya Dinkar Patil, MD, FACP, Cleveland Clinic
Education Session: [On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer](#)
Speaker, “The Next Frontier: Understanding and Overcoming Resistance to Targeted Therapy and Immunotherapy”
Friday, May 31, 2019, 2:45 PM – 4:00 PM, S100bc

**Eric Kodish, MD**, Cleveland Clinic
Chair, Education Session: [Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges](#)
Speaker, “Ethical Care Practices: Respecting Cultural and Societal Differences to Safeguard the Therapeutic Relationship”
Monday, June 3, 2019, 8:00 AM – 8:20 AM, S504

**Andrew E. Sloan, MD, FACS**, University Hospitals Cleveland Medical Center
Interactive Case-Based Session: [Bringing New and Innovative Glioblastoma Treatments to Daily Practice](#)
Speaker, “New Surgical Toolbox for Glioblastoma Surgery: Integration of 5-ALA, Intraoperative MRI and Molecular Diagnostics”
Monday, June 3, 2019, 8:00 AM – 8:40 AM, E451

**Jennifer S. Yu, MD, PhD**, Cleveland Clinic
Chair, Education Session: [Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?](#)
Speaker, “To Radiate or Not to Radiate: Nuances of Radiation Therapy for Low-Grade Gliomas”
Cancer Center members indicated in **BOLD**

Monday, June 3, 2019, 10:00 AM – 10:15 AM, E451

**Brian I. Rini, MD, FACP**, Cleveland Clinic Taussig Cancer Institute
Panelist, Interactive Case-Based Session: **Emerging New Standards of Care for Advanced Kidney Cancer**
Monday, June 3, 2019, 11:30 AM – 12:30 PM, E451

**Alberto J. Montero, MD, MBA**, NSABP Foundation, Cleveland Clinic
Interactive Case-Based Session: **Controversies in Breast Cancer Adjuvant Therapy**
Speaker, “Case 1. Managing Residual ER-Negative Disease after Neoadjuvant Chemotherapy”
Monday, June 3, 2019, 1:15 PM – 2:15 PM, Hall D2

**Brian T. Hill, MD, PhD**, Cleveland Clinic
Education Session: **Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia**
Speaker, “Maintenance After Frontline Therapy in Follicular Lymphoma? An Appropriate Management Plan for Selected Patients”
Tuesday, June 4, 2019, 8:45 AM – 9:00 AM, E451

<table>
<thead>
<tr>
<th><strong>Clinical Science Symposium</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kamal Chamoun, MD</td>
</tr>
<tr>
<td>Evidence, Care, Impact: Making Inroads Against Cancer Disparities</td>
</tr>
<tr>
<td>First Author, ([LBA107] Insurance status and survival of multiple myeloma (MM) patients. )</td>
</tr>
<tr>
<td>Sunday, June 2, 2019, 10:21 AM – 10:33 AM, Hall D1</td>
</tr>
<tr>
<td>Authors: Kamal Chamoun, <strong>Marcos J.G. De Lima</strong>, Paolo Fabrizio Caimi, Pingfu Fu, Shufen Cao, Folashade Otegbeye, Seema Patel, Naveed Ali, Stanton L. Gerson, Kirsten M Boughan, Ravi Kumar Kyasaram, Ehsan Malek; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; Department of Biostats and Epidemiology, Case Western Reserve University, Cleveland, OH; Adult Malignant Hematology, Seidman Cancer Center, Cleveland, OH; Case Western Reserve University Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Cleveland Medical Center, Cleveland, OH; Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Oral Abstract Sessions</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(102) Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer</strong></td>
</tr>
<tr>
<td>Oral Abstract Session: Lung Cancer-Non-Small Cell Metastatic</td>
</tr>
<tr>
<td>Saturday, June 1, 2019, 8:00 AM – 9:30 AM, Hall D1</td>
</tr>
<tr>
<td>Authors: Ferdinandos Skoulidis, Kathryn Cecilia Arbour, Matthew David Hellmann, Pradnya Dinkar Patil, Melina Elpi Marmarelis, Mark M. Awd, Joseph Christopher Murray, Jessica Hellyer, Justin F. Gainor, Anastasios Dimou, Christine M. Bestvina, Catherine A. Shu, Jonathan W. Riess, Collin Michael Blakely, Chad Victor Pecot, Laura Mezquita, Fabrizio Tabbò, Matthias Scheffler, Vassiliki Papadimitrakopoulou, John Heymach; The University of Texas MD Anderson Cancer Center, Houston, TX; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Cleveland Clinic, Cleveland, OH; Brigham and Women’s Hospital, Boston, PA; Massachusetts General Hospital, Cambridge, MA; Johns Hopkins Oncology, Baltimore, MD; Stanford Cancer Institute, Stanford, CA;</td>
</tr>
</tbody>
</table>
Cancer Center members indicated in **BOLD**

Massachusetts General Hospital, Boston, MA; University of Colorado Cancer Center, Aurora, CO; University of Chicago, Chicago, IL; Columbia University Medical Center, New York, NY; UC Davis Comprehensive Cancer Center, Sacramento, CA; University of California San Francisco, San Francisco, CA; UNC Lineberger Cancer Ctr, Chapel Hill, NC; Medical Oncology Department, Gustave Roussy, Villejuif, France; Universita degli Studi di Torino, Torino, Italy; Lung Cancer Group Cologne, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Dept. I of Internal Medicine, Cologne, Germany

**(8001) E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma**

Oral Abstract Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Sunday, June 2, 2019, 9:45 AM – 12:45 PM, E451

Authors: Sagar Lonial, Susanna J. Jacobus, Matthias Weiss, Shaji Kumar, Robert Z. Orlowski, Jonathan L. Kaufman, Abdulraheem Yacoub, Francis Buadi, Timothy E. O'Brien, Jeffrey Matous, Daniel M. Anderson, Robert Emmons, Madhav V. Dhodapkar, Lynne I. Wagner, S. Vincent Rajkumar; Winship Cancer Institute of Emory University, Atlanta, GA; Dana-Farber Cancer Institute, Boston, MA; ThedaCare, Appleton, WI; Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Kansas Cancer Center, Westwood, KS; Division of Hematology, Mayo Clinic, Rochester, MN; MetroHealth Medical Center/Case Western Reserve University School of Medicine, Cleveland, OH; Colorado Blood Cancer Institute, Denver, CO; Regions Hospital, St Paul, MN; Ochsner Cancer Institute, New Orleans, LA; Yale School of Medicine, New Haven, CT; Northwestern University Feinberg School of Medicine, Chicago, IL

**(2508) First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), + cemiplimab in patients (pts) with advanced malignancies**

Oral Abstract Session: Developmental Immunotherapy and Tumor Immunobiology

Monday June 3, 8:00 AM to 11:00 AM, Hall D2

Authors: Kyriakos P. Papadopoulos, Nehal J. Lakhani, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Timothy A Yap, Afschin Dowlati, Robert G. Maki, Filipa Lynce, Susanna Varkey Ulahannan, Karen Kelly, Tasha Nicholle Sims, Amy-Lee Bredlau, Derrick Bramble, Ana Gonzalez Ortiz, Min Zhu, Huanyu Chen, Maria Karasarides, Glenn Kroog; South Texas Accelerated Research Therapeutics, San Antonio, TX; START-Midwest, Grand Rapids, MI; Sarah Cannon Research Institute, Nashville, TN; Washington University School of Medicine, St. Louis, MO; Henry Ford Hospital, Detroit, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Division of Medical Oncology and Hematology, Department of Medicine, Moniter Cancer Center, Lake Success, NY; Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC; Stephenson Cancer Center, Oklahoma City, OK; UC Davis Comprehensive Cancer Center, UC Davis Health, Sacramento, CA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY

**(4500) Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as firstline therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.**

Oral Abstract Session: Genitourinary (Nonprostate) Cancer

Monday June 3, 8:00 AM to 8:12 AM, Arie Crown Theater

Author(s): Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frederic Pouliot, Denis Soulieres, Bohuslav Melichar, Ihor Vynnychenko, Sergio Jobim Azevedo, Delphine Borchelli, Raymond S. McDermott, Jens Bedke, Satoshi Tamada, Shuyan Wan, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Fox Chase Cancer Center, Philadelphia, PA; Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipro, Ukraine; Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation; The Christie NHS Foundation Trust, Manchester, United Kingdom; Central Clinical Hospital with Outpatient Clinic, Moscow, Russian Federation; CHU de Québec and Université Laval, Quebec City, QC, Canada; Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech
Republic; Sumy State University, Sumy Regional Oncology Center, Sumy, Ukraine; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centre Antoine Lacassagne, Université Côte d’Azur, Nice, France; Adelaide and Meath Hospital and University College Dublin, Dublin, Ireland; Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany; Osaka City University Hospital, Osaka, Japan; Merck & Co., Inc., Kenilworth, NJ; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

(2006) Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors
Oral Abstract Session: Central Nervous System Tumors
Monday June 3, 3:15 PM to 3:27 PM, S102
Authors: Alexander E. Drilon, Steven G. DuBois, Anna F. Farago, Birgit Geoerger, Juneko E. Grilley-Olson, David S. Hong, Davendra Sohal, Cornelis Martinus van Tilburg, David Simon Ziegler, Nora Ku, Michael Craig Cox, Shivani Nanda, Barrett H. Childs, Francois P. Doz; Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY; Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA; Cancer Center, Massachusetts General Hospital, Boston, MA; Institut Gustave Roussy, Villejuif, France; University of North Carolina Hospitals, Chapel Hill, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia; Loxo Oncology, Inc., South San Francisco, CA; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ; Institut Curie, Paris, France

(9504) United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma
Oral Abstract Session: Melanoma/Skin Cancers
Tuesday, June 4, 9:45 AM – 12:45 PM, S406
Authors: Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary Irvin Cohen, Omid Hamid, Laura Fulper Hutchins, Jeffrey Alan Sokman, Harriet M. Kluger, Vernon K. Sondak, Henry B. Koon, Donald P. Lawrence, Kari Lynn Kendra, David R. Minor, Carrie B. Lee, Mark R. Albertini, Lawrence E. Flaherty, Teresa M. Petrella, John M. Kirkwood; Emory University and Winship Cancer Institute, Atlanta, GA; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Pittsburgh Medical Center, Pittsburgh, PA; Cancer Center At GBMC, Baltimore, MD; The Angeles Clinic and Research Institute, Los Angeles, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Vanderbilt University Ingram Cancer Center, Nashville, TN; Yale School of Medicine and Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT; Moffitt Cancer Center, Tampa, FL; Case Western Reserve University, Cleveland, OH; Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston, MA; The Ohio State University Comprehensive Cancer Center, Department of Internal Medicine, Columbus, OH; California Pacific Medical Center Research Institute, San Francisco, CA; Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Wisconsin, Madison, WI; Karmanos Cancer Institute, Detroit, MI; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

Poster Discussion Sessions

(5020) HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial
Poster Session: Genitourinary (Nonprostate) Cancer
Saturday, June 1, 2019 4:30 – 6:00 PM, Arie Crown Theater

ASCO Annual Meeting 2019
[4]
Authors: Jason W.D. Hearn, Christopher Sweeney, Nima Almassi, Chad A. Reichard, Chandana A. Reddy, **Brian Hobbs**, David Frazier Jarrard, Yu-Hui Chen, Robert Dreicer, **Jorge A. Garcia**, Michael Anthony Carducci, Robert S. DiPaola, **Nima Sharifi**; University of Michigan, Ann Arbor, MI; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; UT MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH; University of Wisconsin Hosp and Clinics, Madison, WI; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Virginia, Charlottesville, VA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, MD; University of Kentucky, Lexington, KY

(6528) Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma
Poster Session: Health Services Research, Clinical Informatics, and Quality of Care
Saturday, June 1, 2019 4:30 – 6:00 PM, S102
Authors: Nathaniel Rosko, Sarah Lee, Christy Joy Samaras, Alex V. Mejia, Faiz Anwer, Beth Faiman, Saveta Mathur, Kimberly Hamilton, Janice Reed, Mary Ann Karam, Jason Neil Valent; Cleveland Clinic, Cleveland, OH; Taussig Cancer Ctr, Chagrin Falls, OH; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Cleveland Clinic, Eastlake, OH

(2016) SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update
Poster Session: Central Nervous System Tumors
Sunday, June 2, 2019, 4:30 PM – 6:00 PM, S404
Authors: **Manmeet Singh Ahluwalia**, David A. Reardon, Ajay P Abad, William T. Curry, Eric T. Wong, Ahmed Belal, Jingxin Qiu, Kathleen Mogensen, Cathy Schieler, Alan Hutson, Danielle Casucci, Laszlo Mechtler, Erik J UhImann, Michael J Ciesielski, Robert Fenstermaker; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Massachusetts General Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Cleveland Clinic, Cleveland, OH; Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Eastlake, OH; Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, MD; University of Kentucky, Lexington, KY

(9002) ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC
Poster Session: Lung Cancer—Non-Small Cell Metastatic
Monday, June 3, 8:00 AM – 11:00 AM, Hall B1
Authors: Suresh S. Ramalingam, Suzanne Eleanor Dahlberg, Chandra Prakash Belani, Joel N. Saltzman, Gopakumar S. Nambudiri, John McCann, Jerome D. Winegarden, Mohammed Azher Kassem, Mohamed K. Mohamed, Jan M. Rothman, Alan P. Lyss, Leora Horn, Tom Stinchcombe, Joan H. Schiller, ECOG-ACRIN Cancer Research Group; Winship Cancer Institute, Emory University, Atlanta, GA; Dana-Farber Cancer Institute, Boston, MA; Penn State Hershey Cancer Institute, Hershey, PA; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Health East Cancer Care, Woodbury, MN; Baystate MedcI Ctr, Springfield, MA; Ann Arbor Hem Onc Assocs, Ypsilanti, MI; Mt.Sinai Hosp, Chicago, IL; Cone Health Center at Wesley Long, Greensboro, NC; The Regional Cancer Center, Erie, PA; Missouri Baptist Cancer Ctr, St Louis, MO; Vanderbilt University Medical Center, Nashville, TN; Duke Cancer Institute, Durham, NC; The University of Texas Southwestern Medical Center, Dallas, TX

(4016) Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Monday, June 3, 2019, 3:00 PM – 4:00 PM, E450
Authors: Saroj Vadhan-Raj, Mairead Geraldine McNamara, Marino Venerito, Hanno Riess, Eileen Mary O’Reilly, Michael J. Overman, Xiao Zhou, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Alok A. Khorana;
The University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TX; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum, Magdeburg, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; Janssen Research & Development, Raritan, NJ; Janssen Scientific Affairs, LLC, Titusville, NJ; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

**(1507) Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies**
Poster Session: Cancer Prevention, Hereditary Genetics, and Epidemiology
Monday, June 3, 2019, 4:30 PM – 6:00 PM, S103
Authors: Madison Conces, Ying Ni, Peter Bazeley, Bhumika Patel, Pauline Funchain, Hetty E Carraway;
Cleveland Clinic, Cleveland, OH; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

**(4512) Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis**
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 4:30 PM – 6:00 PM, Hall D2
Authors: Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert E. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh A. Huseni, Susheela Carroll, Roxana Ioana Sufan, Christina Schiff, Michael B. Atkins; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom; Beth Israel Deaconess Medical Center, Boston, MA; Gustave Roussy, Villejuif, France; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; The Christie NHS Foundation Trust, Manchester, United Kingdom; Azienda Ospedaliera S.Maria, Terni, Italy; Department of Urology, University of Tübingen, Tübingen, Germany; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; IRCCS San Matteo University Hospital Foundation, Pavia, Italy; CHU Hopitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France; Ashford Cancer Centre Research, Kurralta Park, SA, Australia; MD Anderson Cancer Center Madrid, Madrid, Spain; Genentech, Inc., San Francisco, CA; Genentech, Inc., South San Francisco, CA; Genetech Inc, South San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

**(4513) CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features**
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 4:30 PM – 6:00 PM, Hall D2
Authors: David F. McDermott, Toni K. Choueiri, Robert J. Motzer, Osvaldo Rudy Aren, Saby George, Thomas Powles, Frede Donskov, Michael Roger Harrison, Jeronimo Rafael Rafael Rodriguez Cid, Yuko Ishii, M. Brent McHenry, Sabeen Fatima Mekan, Brian I. Rini, Nizar M. Tannir; Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Centro de Investigación Clínica Bradford Hill, Santiago, Chile; Roswell Park Cancer Institute, Buffalo, NY; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom; Aarhus University Hospital, Aarhus, Denmark; Duke Cancer Institute, Durham, NC; Centro Oncológico, Hospital Medica Sur, Mexico City, Mexico; Bristol-Myers Squibb, Princeton, NJ; Montefiore Cancer Ctr, New York, NY; Cleveland Clinic
Taussig Cancer Institute, Cleveland, OH; University of Texas MD Anderson Cancer Center, Houston, TX

(4515) Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC)
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 4:30 PM – 6:00 PM, Hall D2
Authors: Sumanta K. Pal, David F. McDermott, Michael B. Atkins, Bernard Escudier, Brian I. Rini, Robert J. Motzer, Lawrence Fong, Richard Wayne Joseph, Stephane Oudard, Alain Ravaud, Sergio Bracarda, Cristina Suarez Rodriguez, Elaine Tat Lam, Toni K. Choueiri, Beiying Ding, Caroleen Quach, Kenji Hashimoto, Christina Schiff, Elisabeth Piault, Thomas Powles; City of Hope National Medical Center, Duarte, CA; Beth Israel Deaconess Medical Center, Boston, MA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Gustave Roussy, Villejuif, France; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; University of California San Francisco, San Francisco, CA; Mayo Clinic Hospital, Jacksonville, FL; Paris Descartes University, Paris, France; CHU Hopitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France; Ospedale San Donato, Arezzo, Italy; Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; University of Colorado Cancer Center, Denver, CO; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; Genentech, Inc., South San Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom

(7010) Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial
Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Monday, June 3, 2019, 4:30 PM – 6:00 PM, E450
Authors: B. Douglas Smith, Cristina Papayannidis, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Albert Oriol, Gary J. Schiller, Anna Candoni, Catriona HM Jamieson, Caroline J. Hoang, Wendy Ma, Mirjana Zeremska, Ashleigh O’Connell, Geoffrey Chan, Jorge E. Cortes; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy; Hannover Medical School, Hannover, Germany; Hospital Universitari i Politècnic La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain; University of California, Los Angeles, Los Angeles, CA; Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Udine, Italy; University of California San Diego Moores Cancer Center, San Diego, CA; Pfizer Inc., New York, NY; Pfizer Oncology, New York, NY; Pfizer Inc, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX

(7517) Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium
Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Monday, June 3, 2019, 11:30 AM – 1:00 PM, E450
Authors: Jay Y. Spiegel, Saurabh Dahiya, Michael D. Jain, Loretta J. Nastoupil, Armin Ghobadi, Yi Lin, Matthew Alexander Lunning, Patrick Michael Reagan, Joseph McGuirk, Abhinav Deol, Javier Munoz, Frederick Lundry Locke, Sattva Swarup Neelapu, John S Tamaresis, Aaron Rapoport, David Bernard Miklos, Brian Thomas Hill; Stanford University, Stanford, CA; Bay State Medc Centre, Holyoke, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX; Washington University in St. Louis, St. Louis, MO; Mayo Clinic, Rochester, MN; University of Nebraska Medical Center, Omaha, NE; University of Rochester Medical Center, Rochester, NY; Kansas City Care Center, Kansas City, MO; Blood and Marrow Transplant Program, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Banner MD Anderson Cancer Center, Gilbert, AZ; The University of Texas MD Anderson Cancer Center, Houston, TX; Greenebaum Cancer Center, Baltimore, MD; Stanford University School of Medicine, Stanford, CA; Cleveland Clinic, Cleveland, OH

ASCO Annual Meeting 2019
**Poster Sessions**

(2539) Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Saturday, June 1, 2019, 8:00 AM – 11:00 AM, Hall A (Board #183)
Authors: Paolo Fabrizio Caimi, Jane Reese, Folashade Otegbeye, Dina Schneider, Kamal Chamoun, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Winfried Kruger, Andrew Worden, Michael Kadan, Ehsan Malek, Leland L. Metheny, Benjamin K. Tomlinson, Rafick-Pierre Sekaly, David Wald, Rimas Orentas, Boro Dropulic, Marcos J.G. De Lima; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH; Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, MD; Case Western Reserve University, Cleveland, MD; Case Western Reserve University, Cleveland, OH; Seattle Children's Ben Towne Center for Childhood Cancer Research, Seattle, WA

(2541) Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Saturday, June 1, 2019, 8:00 AM – 11:00 AM, Hall A (Board #185)
Authors: Arjun Khunger, Julie Rytlewski, Erik C. Yusko, Ahmad A. Tarhini; Cleveland Clinic, Cleveland, OH; Adaptive Biotechnologies, Seattle, WA; Case Comprehensive Cancer Center/Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(2588) Intra and perinodular CT delta radiomic features associated with early response to predict overall survival (OS) in immunotherapy-treated non-small cell lung cancer (NSCLC): A multi-site multi-agent study
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Authors: Prateek Prasanna, Mohammadhadi Khorrami, Amit Gupta, Pradnya Dinkar Patil, Monica Khunger, Priya Velu, Kaustav Bera, Mehdi Aliou, Vamsidhar Velcheti, Anant Madabhushi; Case Western Reserve University, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Hospital of the University of Pennsylvania, Philadelphia, PA; NYU Langone, Perlmutter Cancer Center, New York, NY; Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH

(TPS2649) Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Saturday, June 1, 2019, 8:00 AM – 11:00 AM, Hall A (Board #290b)
Authors: Ulka N. Vaishampayan, Mayer N. Fishman, Daniel C. Cho, Christopher J. Holmes, Vamsidhar Velcheti, David F. McDermott, William J. Slichenmyer, Emily Putiri, Heather Losey, Sean Rossi, Marc S. Ernstoff; Wayne State University, Detroit, MI; Moffitt Cancer Center, Tampa, FL; New York University Langone Hospitals, New York, NY; Case Western Reserve University, Cleveland, OH; Beth Israel Deaconess Medical Center, Boston, MA; Alkermes, Inc, Waltham, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY

(3063) First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Saturday, June 1, 2019, 8:00 AM – 11:00 AM, Hall A (Board #55)
Authors: Debbie Robbrecht, Ferry Eskens, Emiliano Calvo, Xiaomin He, Hiroshi Hirai, Nital Soni, Natalie Cook, Afshin Dowlati, Angelica Fasolo, Victor Moreno, Johann S. De Bono; Erasmus MC, Rotterdam, Netherlands; Erasmus MC Cancer Institute, Rotterdam, Netherlands; START Madrid-Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, Spain; Taiho Oncology, Princeton, NJ; Tsukuba Research Institute, Ibaraki, Japan; Christie Hospital, Manchester, United Kingdom; UH Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; San Raffaele Hospital, Milan, Italy; START Madrid-FJD, Madrid, Spain; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom

(3122) Larotrectinib efficacy and safety in adult TRK fusion cancer patients
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Saturday, June 1, 2019, 8:00 AM – 11:00 AM, Hall A (Board #114)
Authors: David S. Hong, Shivaani Kummar, Anna F. Farago, Ulrik Niels Lassen, Jordan Berlin, Russell J. Schilder, Raymond S. McDermott, Jyoti D. Patel, Afshin Dowlati, Robert Charles Doebele, Daniel Shao-Weng Tan, James J. Lee, Shivani Nanda, Barrett H. Childs, Nora Ku, Alexander E. Drilon, David Michael Hyman; The University of Texas MD Anderson Cancer Center, Houston, TX; Stanford Cancer Center, Stanford University, Palo Alto, CA; Cancer Center, Massachusetts General Hospital, Boston, MA; Department of Oncology, Rigshospitalet, Copenhagen, Denmark; Vanderbilt University, Nashville, TN; Thomas Jefferson University, Philadelphia, PA; St Vincent’s University Hospital and Cancer Trials Ireland, Dublin, Ireland; The University of Chicago Medical Center, Chicago, IL; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; University of Colorado, Denver, CO; National Cancer Center, Singapore, Singapore; University of Pittsburgh Medical Institute, Pittsburgh, PA; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ; Loxo Oncology, Inc., South San Francisco, CA; Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY

(5020) HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial
Poster Session: Genitourinary (Nonprostate) Cancer
Saturday, June 1, 2019 1:15 – 4:15 PM, Hall A (Board #132)
Authors: Jason W.D. Hearn, Christopher Sweeney, Nima Almassi, Chad A. Reichard, Chandana A. Reddy, Brian Hobbs, David Frazier Jarrard, Yu-Hui Chen, Robert Dreicer, Jorge A. Garcia, Michael Anthony Carducci, Robert S. DiPaola, Nima Sharifi; University of Michigan, Ann Arbor, MI; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; UT MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH; University of Wisconsin Hosp and Clinics, Madison, WI; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Virginia, Charlottesville, VA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, MD; University of Kentucky, Lexington, KY

(5060) Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical prostatectomy: A multisite study
Poster Session: Genitourinary (Prostate) Cancer
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #172)
Authors: Patrick Leo, Andrew Janowczyk, Robin Elliott, Nafiseh Janaki, Chad A. Reichard, Chandana A. Reddy, Kojis Yamoha, Timothy Rebbeck, Natalie Shih, Francesca Khani, Brian D. Robinson, Lauri Eklund, Otto Ettala, Pekka Taimen, Peter Bostrom, Michael D Feldman, Sanjay Gupta, Priti Lal, Anant Madabhushi; Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH; Case Western Reserve University, Department of Pathology, Cleveland, OH; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Self-employed, Lleida, Spain;
Cancer Center members indicated in BOLD

Thomas Jefferson Univ Hosp, Philadelphia, PA; Harvard University, T.H. Chan School of Public Health and Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Weill Cornell Medical College, New York, NY; Department of Pathology & Laboratory Medicine, Engleider Institute for Precision Medicine, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY; University of Turku, Turku, Finland; Turku University Hospital, Urology Department, Turku, Finland; University of Pennsylvania, Department of Pathology, Philadelphia, PA; Case Western Reserve University, Department of Urology, Cleveland, OH

(5071) Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration
Poster Session: Genitourinary (Prostate) Cancer
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #183)
Authors: Iris Yeong- Fung Sheng, Yu-Wei Chen, Moshe Chaim Ornstein, Timothy D. Gilligan, Brian I. Rini, Jorge A. Garcia; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(6071) Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC)
Poster Session: Head and Neck Cancer
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #60)
Authors: Katharine Andress Rowe Price, Ashish V. Chintakuntlawar, Robert Leonard Foote, Yolanda I. Garces, Daniel Ma, Michelle A. Neben-Wittich, Eric J. Moore, Jan C. Kasperbauer, Daniel L. Price, Jeffrey R. Janus, Kathryn M. Van Abel, Jessica Lyn Geiger; Mayo Clinic, Rochester, MN; Department of Radiation Oncology, Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH

(6080) Outcomes of post-operative treatment with concurrent chemoradiotherapy (CRT) in high risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration
Poster Session: Head and Neck Cancer
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #69)
Authors: Jessica Lyn Geiger, Neil McIver Woody, C. Jillian Tsai, Ahmed I. Ghanem, Neal Dunlap, Howard Liu, Brian B. Burkey, Eric Lamarr, Jamie Ku, Joseph Scharpf, Nikhil Purushottam Joshi, Jimmy J. Caudell, Farzan Siddiqui, Sandro Porceddu, Nancy Y. Lee, Shlomo A. Koyfman, David J. Adelstein; Cleveland Clinic, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Henry Ford Hospital/Alexandria University, Detroit, MI; University of Louisville, James Graham Brown Cancer Center, Louisville, KY; Princess Alexandra Hospital, Brisbane, Australia; All India Institute of Medical Sciences, New Delhi, India; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Henry Ford Health System, Detroit, MI; School of Medicine, University of Queensland, Herston, Queensland, Australia; Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Australia

(6528) Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma

ASCO Annual Meeting 2019
[10]
Cancer Center members indicated in BOLD

Poster Session: Health Services Research, Clinical Informatics, and Quality of Care  
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #219)  
Authors: Nathaniel Rosko, Sarah Lee, Christy Joy Samaras, Alex V. Mejia, Faiz Anwer, Beth Faiman, Saveta Mathur, Kimberly Hamilton, Janice Reed, Mary Ann Karam, Jason Neil Valent; Cleveland Clinic, Cleveland, OH; Taussig Cancer Ctr, Chagrin Falls, OH; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Cleveland Clinic, Eastlake, OH

(6557) Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC)  
Poster Session: Health Services Research, Clinical Informatics, and Quality of Care  
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #248)  
Authors: Davendra Sohal, Julien Doudement, Ben George, Brian Michael Alexander, Stefan C. Grant, William Y. Kim, Martin Gutierrez, William Kevin Kelly, Karen E. Knudsen, John McPherson, Christopher J. Hoimes, Elizabeth J. Davis, Gaurav Singal, Jennifer Webster, Lindsay Chan, Massimo Cristofanilli, Vincent A. Miller; Cleveland Clinic, Cleveland, OH; Foundation Medicine, Cambridge, MA; Froedtert & the Medical College of Wisconsin, Milwaukee, WI; Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA; Comprehensive Cancer Center of Wake Forest Baptist Health, Winston Salem, NC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Hackensack University Medical Center, Hackensack, NJ; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; The Sidney Kimmel Cancer Center at Jefferson University, Philadelphia, PA; University of California Davis Comprehensive Cancer Center, Sacramento, CA; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Vanderbilt University, Nashville, TN; Foundation Medicine, Inc., Cambridge, MA; Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

(6565) Development of a financial navigation program to ease the burden of financial toxicity  
Poster Session: Health Services Research, Clinical Informatics, and Quality of Care  
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #256)  
Authors: Melissa Monak, Kimberly Bell, Antoinette Whitt; Cleveland Clinic, Cleveland, OH; Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH

(6622) Virtual visits for children, adolescents, and young adults with cancer  
Poster Session: Health Services Research, Clinical Informatics, and Quality of Care  
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #313)  
Authors: Peter Meade Anderson, Stacey Zahler, Lynn Harter, Rabi Hanna; Cleveland Clinic, Cleveland, OH; Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH; Ohio University, Athens, OH

(6597) Association between age, risk of severe (Grade 3-4) immune-related adverse events (sirAE), and mortality in patients receiving immune checkpoint inhibitors (ICI)  
Poster Session: Health Services Research, Clinical Informatics, and Quality of Care  
Saturday, June 1, 2019, 1:15 PM – 4:15 PM, Hall A (Board #288)  
Authors: Asrar Alamdadi, Ariel Ann Nelson, Sadeer Al-Kindi, Fang Liu, Prateek Mendiratta, Ankit Mangla, Nikhil H. Ramaiya, Christopher J. Hoimes; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals - Seidman Cancer Center, Cleveland, OH; University Hospitals - Harrington Discovery Institute, Cleveland, OH; University Hospitals - Seidman Cancer Center, Cleveland, OH; University Hospitals of Seidman Cancer Center/ Case Comprehensive Cancer Center, Cleveland, OH; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center/ Case Comprehensive Cancer Center, Cleveland, OH
(547) Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database
Poster Session: Breast Cancer – Local/Regional/Adjuvant
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #39)
Authors: Zeina A. Nahleh, Brian Hobbs, Elizabeth Elimimian, Wei (Auston) Wei, Annie Gupta, Cassann N. Blake; Cleveland Clinic Florida, El Paso, TX; Taussig Cancer Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Fl, Weston, FL; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Florida, Weston, FL

(593) Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from pretreatment breast MRI
Poster Session: Breast Cancer – Local/Regional/Adjuvant
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #85)
Authors: Manasa Vulchi, Mohammed El Adoui, Nathaniel Braman, Paulette Turk, Maryam Etesami, Stylianos Drisis, Donna Plecha, Mohammed Benjelloun, Anant Madabhushi, Jame Abraham; Cleveland Clinic, Cleveland, OH; Faculty of Engineering/Computer Science Unit/University Of Mons/Belgium, Mons, Belgium; Case Western Reserve University, Cleveland, OH; Yale School of Medicine, New Haven, CT; Institut Jules Bordet, Brussels, Belgium; University Hospitals Case Medical Center, Cleveland, OH; Case Western Reserve University Case School of Engineering, Cleveland, OH; NSABP Foundation and Cleveland Clinic, Cleveland, OH

(1032) Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis
Poster Session: Breast Cancer – Metastatic
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #113)
Authors: Abby Statler, Annie Gupta, Cassann N. Blake, Wei (Auston) Wei, Brian Hobbs, Zeina A. Nahleh; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Florida, Weston, FL; Cleveland Clinic Foundation, Cleveland, OH; Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

(1033) Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis
Poster Session: Breast Cancer – Metastatic
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #114)
Authors: Abby Statler, Zeina A. Nahleh, Brian Hobbs, Wei (Auston) Wei, Annie Gupta, Cassann N. Blake; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Florida, El Paso, TX; Taussig Cancer Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Florida, Weston, FL

(1095) Clinical characteristics and outcome of metaplastic breast cancer: A retrospective tertiary care center experience
Poster Session: Breast Cancer – Metastatic
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #176)
Authors: Bicky Thapa, Salome Arobelidze, Xuefei Jia, Hassan Awada, Tariq Zuheir Kewan, Fahrettin Covut, Mita Patel, Hamed Daw, Timothy Peter Spiro, Abdo S. Haddad; Department of Medicine, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH; Akron General Medcl Ctr, Maple Heights, OH; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH; Fairview Hospital-Cleveland Clinic, Cleveland, OH
(2016) SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update
Poster Session: Central Nervous System Tumors
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #205)
Authors: Manmeet Singh Ahluwalia, David A. Reardon, Ajay P Abad, William T. Curry, Eric T. Wong, Ahmed Belal, Jingxin Qiu, Kathleen Mogensen, Cathy Schilero, Alan Hutson, Danielle Casucci, Laszlo Mechtler, Erik J UhIlmann, Michael J Ciesielski, Robert Fenstermaker; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Massachusetts General Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Cleveland Clinic, Cleveland, OH; Roswell Park Cancer Institute, Buffalo, NY; Dent Neurologic Institute, Buffalo, NY

(2017) Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM
Poster Session: Central Nervous System Tumors
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #206)
Authors: Michael Lim, Xiaobu Ye, Anna F. Piotrowski, Arati Suvas Desai, Manmeet Singh Ahluwalia, Tobias Walbert, Joy D. Fisher, Serena Desideri, Zineb Belcaid, Christina Jackson, Louis B. Nabors, Patrick Y. Wen, Stuart A. Grossman; The Johns Hopkins Hospital, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Memorial Sloan Kettering Cancer Center, New York, NY; Hospital of the University of Pennsylvania, Philadelphia, PA; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH; Henry Ford Hospital, Detroit, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Johns Hopkins University SOM, Baltimore, MD; University of Alabama at Birmingham, Birmingham, AL; Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA; Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

(2027) Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM)
Poster Session: Central Nervous System Tumors
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #216)
Authors: Roy E. Strowd, Benjamin M. Ellingson, Patrick Y. Wen, Manmeet Singh Ahluwalia, Anna F. Piotrowski, Arati Suvas Desai, Jennifer Leigh Clarke, Frank S. Lieberman, Serena Desideri, Louis B. Nabors, Xiaobu Ye, Stuart A. Grossman; Wake Forest School of Medicine, Winston-Salem, NC; University of California Los Angeles, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Hospital of the University of Pennsylvania, Philadelphia, PA; University of California, San Francisco, San Francisco, CA; University of Pittsburgh Medical Center, Pittsburgh, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; University of Alabama at Birmingham, Birmingham, AL; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

(2062) A phase I study of MGMT-P140K transfected hematopoetic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit
Poster Session: Central Nervous System Tumors
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #251)
Authors: Andrew E. Sloan, Lisa Roger, Chris Murphy, Jane Reese, Hillard M. Lazarus, Boro Dropulic, Stanton L. Gerson; University Hospital Case Medical Center, Cleveland, OH; University Hospitals, Cleveland, OH; Seidman Cancer Center, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH;
Cancer Center members indicated in **BOLD**

University Hospital of Cleveland, Cleveland, OH; Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, MD; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

**(2069)** Insight into the brain metastasis journey: Initial survey results from patients and caregivers
Poster Session: Central Nervous System Tumors
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #258)
Authors: Nicole Willmarth, Scott Elder, Avery Fine, **Manmeet Singh Ahluwalia**, **Jill Barnholtz-Sloan**, Priscilla Kaliopi Brastianos, Daniel Brat, Miness P. Mehta, Robin Page, Ralph DeVitto, Debbie Robins; American Brain Tumor Association, Chicago, IL; Penn Schoen Berland (PSB) Research, Washington, DC; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; Departments of Medicine and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, Chicago, IL; Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Core Life Wellness, Libertyville, IL

Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #310)
Authors: Fatemeh Ardeshir-Larijani, Gary Wildey, **Pingfu Fu**, **Afschin Dowlati**; University Hospital Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospital Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

**(8562)** RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday, June 2, 2019, 8:00 AM – 11:00 AM, Hall A (Board #318)
Authors: Luis G. Paz-Ares, David R. Spigel, Christoph Zielinski, Yuanbin Chen, Maria Jove, Oscar Juan Vidal, David Chu, Patricia Rich, Theresa M. Hayes, M Vanesa Gutierrez Calderon, Reyes Bernabe Caro, Alejandro Navarro, **Afschin Dowlati**, Bin Zhang, Yan Moore, Haofei Tiffany Wang, Natalya Nazarenko, Santiago Ponce Aix, Paul A. Bunn; Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and CNIO, Madrid, Spain; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Vienne Cancer Center and Central European Cooperative Oncology Group, Vienna, Austria; Natl Cancer Inst, Ada, MI; Institut Català d’Oncologia, L’Hospitalet, Barcelona, Spain; Hospital Universitario La Fé, Valencia, Spain; North Shore Hematology Oncology Associates, East Setauket, NY; Cancer Treatment Centers of America, Southeastern Regional Medical Center, Newnan, GA; St. John of God Health Care, Warrnambool, VIC, Australia; Regional University Hospital Carlos Haya, Málaga, Spain; Hospital Virgen Del Rocio, Sevilla, Spain; Hospital Universitari Vall d’Hebron, D’hebron, Spain; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Ipsen Bioscience, Boston, MA; Ipsen Bioscience, Cambridge, MA; Hospital 12 de Octubre, Madrid, Spain; University of Colorado Denver, Aurora, CO

**(4016)** Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #121)
Authors: Saroj Vadhan-Raj, Mairead Geraldine McNamara, Marino Venerito, Hanno Riess, Eileen Mary O’Reilly, Michael J. Overman, Xiao Zhou, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, **Alok A.**
Khorana; The University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TX; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum, Magdeburg, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; Janssen Research & Development, Raritan, NJ; Janssen Scientific Affairs, LLC, Titusville, NJ; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

(4137) SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #242)
Authors: Davendra Sohal, Danika L. Lew, Syed A. Ahmad, Namita Gandhi, Mohammad Shaalan Beg, Andrea Wang-Gillam, James Lloyd Wade, Katherine A Guthrie, Andrew M. Lowy, Philip Agop Philip, Howard S. Hochster; Cleveland Clinic, Cleveland, OH; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; University of Cincinnati Medical Center, Cincinnati, OH; The University of Texas Southwestern Medical Center, Dallas, TX; Washington University School of Medicine in St. Louis, St. Louis, MO; Heartland Cancer Research NCORP, Decatur, IL; SWOG Statistics and Data Management Center, and Fred Hutchinson Cancer Research Center, Seattle, WA; UCSD Moores Cancer Center, La Jolla, CA; Karmanos Cancer Institute, Detroit, MI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(4138) Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx)
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #243)
Authors: Michael J. Pishvaian, Edik Matthew Blais, Patricia DeArbeloa, Jonathan Robert Brody, Lola Rahib, Andrew Eugene Hendifar, Sameh Mikhail, Vincent Chung, Davendra Sohal, Vincent J. Picozzi, Kimberly Mason, Lisa Tibbetts, Emily Lyons, Lynn McCormick Matrisian, Subha Madhavan, Emanuel Petricoin; Georgetown University, Washington, DC; Perthera, Inc., Mclean, VA; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Pancreatic Cancer Action Network, Manhattan Beach, CA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Zangmeister Cancer Center, Columbus, OH; City of Hope, Duarte, CA; Cleveland Clinic, Cleveland, OH; Virginia Mason Hospital and Medical Center, Seattle, WA

(4515) Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC)
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #271)
Authors: Sumanta K. Pal, David F. McDermott, Michael B. Atkins, Bernard Escudier, Brian I. Rini, Robert J. Motzer, Lawrence Fong, Richard Wayne Joseph, Stephane Oudard, Alain Ravaud, Sergio Bracarda, Cristina Suarez Rodriguez, Elaine Tat Lam, Toni K. Choueiri, Beiying Ding, Caroleen Quach, Kenji Hashimoto, Christina Schiff, Elisabeth Piault, Thomas Powles; City of Hope National Medical Center, Duarte, CA; Beth Israel Deaconess Medical Center, Boston, MA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Gustave Roussy, Villejuif, France; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; University of California San Francisco, San Francisco, CA; Mayo Clinic Hospital, Jacksonville, FL; Paris Descartes University, Paris, France; CHU Hopitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France; Ospedale San Donato, Arezzo, Italy; Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; University of Colorado Cancer Center, Denver, CO; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; Genentech, Inc., South San
Francisco, CA; Roche Products Ltd., Welwyn Garden City, United Kingdom; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom

(7010) Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial
Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #385)
Authors: B. Douglas Smith, Cristina Papayannidis, Michael Heuser, Pau Montesinos, Mikkael A. Sekeres, Albert Oriol, Gary J. Schiller, Anna Candoni, Catriona HM Jamieson, Caroline J. Hoang, Wendy Ma, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Jorge E. Cortes; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy; Hannover Medical School, Hannover, Germany; Hospital Universitari i Politècnic La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain; University of California, Los Angeles, Los Angeles, CA; Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Udine, Italy; University of California San Diego Moores Cancer Center, San Diego, CA; Pfizer Inc., New York, NY; Pfizer Oncology, New York, NY; Pfizer Inc, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX

(7048) Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial
Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #423)
Authors: Ben Kent Tomlinson, Vijay Reddy, Mark S. Berger, Jennifer Spross, Renee Lichtenstein, Boglarka Gyurkocz; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Actinium Pharmaceuticals, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY

(TPS7066) A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia
Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #438b)
Authors: Daniel J. DeAngelo, Harry Paul Erba, Brian Andrew Jonas, Michael O'Dwyer, Paula Marlton, Gerwin A Huls, Jane Liesveld, Brenda W. Cooper, Bhavana Bhatnagar, Michael Armstrong, William Fogler, Mary Chen, John Magnani, Helen M. Thackray, Anjali S. Advani, Pamela Sue Becker; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham, Birmingham, AL; University of California Davis Comprehensive Cancer Center, Sacramento, CA; The National University of Ireland, Galway, Ireland; Princess Alexandria Hospital and University of Queensland, Brisbane, Australia; Universitair Medisch Centrum Groningen, Groningen, Netherlands; University of Rochester James P Wilmot Cancer Center, Rochester, NY; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; The Ohio State University, Columbus, OH; IQVIA Biotech, Morrisville, NC; GlycoMimetics Inc, Rockville, MD; GlycoMimetics, Rockville, MD; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; University of Washington, Seattle, WA

(7517) Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium
Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #271)
Cancer Center members indicated in **BOLD**

Frederick Lundry Locke, Sattva Swarup Neelapu, John S Tamaresis, Aaron Rapoport, David Bernard Miklos, **Brian Thomas Hill**; Stanford University, Stanford, CA; Bay State MedCt Centre, Holyoke, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX; Washington University in St. Louis, St. Louis, MO; Mayo Clinic, Rochester, MN; University of Nebraska Medical Center, Omaha, NE; University of Rochester Medical Center, Rochester, NY; Kansas City Care Center, Kansas City, MO; Blood and Marrow Transplant Program, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Banner MD Anderson Cancer Center, Gilbert, AZ; The University of Texas MD Anderson Cancer Center, Houston, TX; Greenebaum Cancer Center, Baltimore, MD; Stanford University School of Medicine, Stanford, CA; Cleveland Clinic, Cleveland, OH

**(7543) Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas**

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Monday, June 3, 2019, 8:00 AM – 11:00 AM, Hall A (Board #297)

Authors: **Deepa Jagadeesh**, Steven M. Horwitz, Nancy L. Bartlett, Ranjana H. Advani, Eric D. Jacobsen, Madeleine Duvic, Ashish Gautam, Shangbang Rao, Matthew Onsum, Michelle Fanale, Youn H. Kim; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University School of Medicine in St. Louis and Siteman Cancer Center, St. Louis, MO; Stanford Cancer Institute, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Seattle Genetics Inc, Bothell, WA; Seattle Genetics, Bothell, WA; Seattle Genetics, Inc, Bothell, WA; Department of Dermatology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA

**(4525) Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents**

Poster Session: Genitourinary (Nonprostate) Cancer

Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #351)

Authors: Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Ang Li, Michael Edward Devitt, Alexandra Drakaki, Evan Shreck, Monika Joshi, Pedro Isaacsson Velho, Lucia Alonso, Ariel Ann Nelson, Sandy Liu, Marcus W. Moses, Pedro C. Barata, **Christopher J. Hoimes**, Matt D. Galsky, Guru Sonpavde, Evan Y. Yu, Veena Shankaran, Gary H. Lyman, Petros Grivas; University of Washington, Seattle, WA; Fred Hutch Cancer Research Center, Seattle, WA; University of Virginia, Charlottesville, VA; University of California, Los Angeles, Los Angeles, CA; Montefiore Medical Center, Bronx, NY; Penn State Health Milton S. Hershey Medical Center, Hershey, PA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Hospital National MARQUES VALDECILLA, Santander, Spain; Medical College of Wisconsin, Cleveland, OH; Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA; Tulane University, New Orleans, LA; Cleveland Clinic, Cleveland, OH; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Department of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, School of Medicine, Seattle, WA

**(TPS4593) EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer**

Poster Session: Genitourinary (Nonprostate) Cancer

Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #415b)

Authors: **Christopher J. Hoimes**, Jonathan E. Rosenberg, Daniel Peter Petrylak, Anne-Sophie Carret, Amal Melhem-Bertrandt, Thomas W. Flaig; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Yale School of Medicine, New York, NY; University of Washington, School of Medicine, Seattle, WA; University of California, San Francisco, CA; University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Cleveland Clinic, Cleveland, OH

ASCO Annual Meeting 2019

[17]
Cancer Center members indicated in **BOLD**

Haven, CT; Seattle Genetics, Inc., Bothell, WA; Astellas Pharma US, Inc, Northbrook, IL; Division of Medical Oncology, School of Medicine, University of Colorado, Aurora, CO

**(TPS11629)** Improve: A community-based physical activity intervention to improve functional and health outcomes in older breast cancer survivors: Rationale, design, and methods
Poster Session: Symptoms and Survivorship
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #321a)
Authors: Cynthia Owusu, Nora Nock, Paul Hergenroeder, Kris Austin, Beth Bennett, Stephen Cerne, Halle C. F. Moore, Jean Petkac, Mark D. Schluchter, Kathryn H. Schmitz, Lindsay Atkins, Oghenerukeme Asagba, Leonard Wimbley, Nathan A. Berger; Case Western Reserve University School of Medicine, Cleveland, OH; Metrohealth Medical Center, Cleveland, OH; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University of Pennsylvania, Philadelphia, PA; Case Western Reserve Univ, Cleveland, OH

**(1507)** Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies
Poster Session: Cancer Prevention, Hereditary Genetics, and Epidemiology
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #1)
Authors: Madison Conces, Ying Ni, Peter Bazeley, Bhumika Patel, Pauline Funchain, Hetty E Carraway; Cleveland Clinic, Cleveland, OH; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; The Christie NHS Foundation Trust, Manchester, United Kingdom; Azienda Ospedaliera S.Maria, Terni, Italy; MD Anderson Cancer Center Madrid, Madrid, Spain; Genentech, Inc., San Francisco, CA; Genentech Inc, South San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

**(4512)** Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #338)
Authors: Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert E. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh A. Huseni, Susheela Carroll, Roxana Ioana Sufan, Christina Schiff, Michael B. Atkins; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom; Beth Israel Deaconess Medical Center, Boston, MA; Gustave Roussy, Villejuif, France; London, United Kingdom; Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom; Beth Israel Deaconess Medical Center, Boston, MA; Gustave Roussy, Villejuif, France; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; The Christie NHS Foundation Trust, Manchester, United Kingdom; Azienda Ospedaliera S.Maria, Terni, Italy; Department of Urology, University of Tübingen, Germany; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; IRCCS Sant Matteo University Hospital Foundation, Pavia, Italy; CHU Hopitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France; Ashford Cancer Centre Research, Kurralta Park, SA, Australia; MD Anderson Cancer Center Madrid, Madrid, Spain; Genentech, Inc., San Francisco, CA; Genentech Inc, South San Francisco, CA; Genetech Inc, South San Francisco, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

**(4513)** CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #339)
Authors: David F. McDermott, Toni K. Choueiri, Robert J. Motzer, Osvaldo Rudy Aren, Saby George, Thomas Powles, Frede Donskov, Michael Roger Harrison, Jeronimo Rafael Rafael Rodriguez Cid, Yuku Ishii, M. Brent McHenry, Sabeen Fatima Mekan, Brian I. Rini, Nizar M. Tannir; Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; Memorial Sloan Kettering Cancer Center, New York,

ASCO Annual Meeting 2019
[18]
(4523) Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC)
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #349)
Authors: Jaleh Fallah, Shinjini Ganguly, Hong Li, Wei (Auston) Wei, Aysegul Balyimez, Thirunavukkarasu Sitalaximi, C. Marcela Diaz-Montero, Patricia A. Rayman, Marcelo Lamenza, Priscilla Dann, Donna Company, Rahul D. Tendulkar, Mohamed Abazeed, Jorge A. Garcia, Moshe Chaim Ornstein, Brian I. Rini, Byron H. Lee, Petros Grivas, Omar Y. Mian; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner Research Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of Washington, School of Medicine, Seattle, WA; Cleveland Clinic, Dept. of Radiation Oncology, Dept. of Translational Hematology Oncology Research, Cleveland, OH

(4528) Association of cell-free DNA (cfDNA) levels with myeloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle invasive (MI) and metastatic (met) bladder cancer (BC)
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #354)
Authors: Jaleh Fallah, Shinjini Ganguly, Patricia A. Rayman, Wei (Auston) Wei, Aysegul Balyimez, Thirunavukkarasu Sitalaximi, Marcelo Lamenza, Kevin L. Stephans, Priscilla Dann, Donna Company, Rahul D. Tendulkar, Mohamed Abazeed, Jorge A. Garcia, Brian I. Rini, Byron H. Lee, Moshe Chaim Ornstein, Petros Grivas, Omar Y. Mian, C. Marcela Diaz-Montero; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner Research Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of Washington, School of Medicine, Seattle, WA; Cleveland Clinic, Dept. of Radiation Oncology, Dept. of Translational Hematology Oncology Research, Cleveland, OH

(4572) TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #398)
Authors: Camillo Porta, Elena Verzoni, Bernard Escudier, Sumanta K. Pal, Michael B. Atkins, Thomas E. Hutson, Michael N. Needle, David F. McDermott, Brian I. Rini; Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Gustave Roussy, Villejuif, France; City of Hope National Medical Center, Duarte, CA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Baylor Sammons Cancer Center-Texas Oncology, Dallas, TX; Aveo Oncology, Cambridge, MA; Beth Israel Deaconess Medical Center, Boston, MA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(4575) Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214
Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #401)
Authors: Bernard Escudier, Robert J. Motzer, Nizar M. Tannir, Camillo Porta, Yoshihiko Tomita, Sabeen Fatima Mekan, M. Brent McHenry, Brian I. Rini; Gustave Roussy, Villejuif, France; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan Kettering Cancer Center, New Year
Cancer Center members indicated in **BOLD**

Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; University of Pavia, Pavia, Italy; Niigata University, Niigata, Japan; Bristol-Myers Squibb, Princeton, NJ; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(4576) **Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)**

Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #402)
Authors: Yasser Ged, Ruby Gupta, Cihan Duzgol, Natalie Shapnik, Almedina Redzematovic, Ritesh Kotecha, Martin Henner Voss, Darren R. Feldman, Oguz Akin, Sujata Patil, Robert J. Motzer, Brian I. Rini, Chung-Han Lee; Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

(4578) **Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib**

Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #404)
Authors: Bimal Bhindi, Jeffrey Graham, Connor Wells, Frede Donskov, Felice Pasini, Jae-Lyun Lee, Naveen S. Basappa, Aaron Richard Hansen, Lori Wood, Christian K. Kollmannsberger, Ravindran Kanesvaran, Takeshi Yuasa, D. Scott Ernst, Sandy Srinivas, Brian I. Rini, I. Alex Bowman, Sumanta K. Pal, Toni K. Choueiri, Daniel Yick Chin Heng; University of Calgary, Calgary, AB, Canada; University of Manitoba, Winnipeg, MB, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Oncology, S Maria della Misericordia Hospital, ULSS 18, Rovigo, Italy; Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea; Cleveland Clinic, Cleveland, OH; Princess Margaret Cancer Centre, Toronto, ON, Canada; Dalhousie University, Halifax, NS, Canada; BC Cancer–Vancouver Cancer Centre, Vancouver, BC, Canada; National Cancer Centre Singapore, Singapore, Singapore; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, London Health Sciences Centre and University of Western Ontario,, London, ON, Canada; Stanford University Medical Center, Palo Alto, CA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; UT Southwestern Medical Center, Dallas, TX; City of Hope National Medical Center, Duarte, CA; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA

(9534) **Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy**

Poster Session: Melanoma/Skin Cancers
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #105)
Authors: Mohammed M. Milhem, Georgina V. Long, Christopher J. Hoimes, Asim Amin, Christopher D. Lao, Robert Martin Conny, Jason Hunt, Gregory A. Daniels, Mohammed Almubarak, Montaser F. Shaheen, Theresa Michelle Medina, Minal A. Barve, Sarwan K. Bishnoi, Ehtesham A. Abdi, Michael Jon Chisamore, Biao Xing, Albert Candia, Erick Gamelin, Robert Janssen, Antoni Ribas; University of Iowa, Iowa
(9555) Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy
Poster Session: Melanoma/Skin Cancers
Monday, June 3, 2019, 1:15 PM – 4:15 PM, Hall A (Board #126)
Authors: Asim Amin, Mohammed M. Milhem, Georgina V. Long, Christopher J. Hoimes, Theresa Michelle Medina, Robert Martin Conry, Christopher D. Lao, Gregory A. Daniels, Sunil A. Reddy, Robert Hans Ingemar Andtbacka, Minal A. Barve, Montaser F. Shaheen, Thomas Tueting, Michael Jon Chisamore, Emmett V. Schmidt, Albert Candi, Cynthi Chinedu Obiozor, Erick Gamelin, Robert Janssen, Antoni Ribas; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; University of Iowa, Iowa City, IA; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; University of Colorado, Castle Rock, CO; The Kirkland Clinic at Acton Road, Birmingham, AL; University of Utah, Salt Lake City, UT; University of California, San Diego, La Jolla, CA; Texas Oncology, Dallas, TX; Lyell McEwin Hospital, Adelaide, Australia; Griffith University Gold Coast, The Tweed Hospital, Tweed Heads, Australia; Merck & Co., Inc., Rahway, NJ; Dynavax Technologies, Berkeley, CA; Dynavax Technologies Corporation, Berkeley, CA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA

(e12515) Impact of mastectomy in women with stage IV HER2+ breast cancer
Breast Cancer—Metastatic
Authors: Arslan Babar, Fahrettin Covut, Tariq Zuheir Kewan, Shafia Rahman, Stephen R. Grobmyer, Alberto J. Montero; Department of Medicine, Cleveland Clinic, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; NSABP Foundation, Cleveland Clinic, Cleveland, OH

(e12538) Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR+) metastatic breast cancer
Breast Cancer—Metastatic
Authors: Akaolisa Samuel Ezio, Leticia Varella, Megan Lynn Kruse, Xuefei Jia, Halle C. F. Moore, George Thomas Budd, Jame Abraham, Alberto J. Montero; Cleveland Clinic, Cleveland, OH; Department of Hematology/Oncology, Weill Cornell Medicine, New York, NY; Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; NSABP Foundation and Cleveland Clinic, Cleveland, OH; NSABP Foundation, Cleveland Clinic, Cleveland, OH

(e12571) Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC)
Breast Cancer—Metastatic

ASCO Annual Meeting 2019
Cancer Center members indicated in **BOLD**

Authors: Ariel Ann Nelson, Shivaprasad Manjappa, Yuvraj Choudhary, Cheryl L. Thompson, Jeanine Agler, Bethany Lawrence, Manmeet Singh Ahluwalia, Paula Silverman; University Hospitals - Seidman Cancer Center, Cleveland, OH; Washington University in St. Louis, St. Louis, MO; Univ Hosp, Shaker Hts, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH

**Demographic characteristics of smoldering multiple myeloma patients: A hospital-based study including 11,643 patients**

Authors: Kamal Chamoun, Ravi Kumar Kyasaram, Leland L. Metheny, Molly Gallogly, Paolo Fabrizio Caimi, Stanton L. Gerson, Marcos J.G. De Lima, Ehsan Malek; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Cleveland Medical Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH

**Complex multimorbidity, perceived life expectancy, and routine cancer screening receipt: Differences between older women and men**

Authors: Siran M. Koroukian, David F Warner; Case Western Reserve Univ, Cleveland, OH; University of Nebraska, Lincoln, NE

**Impact of next-generation sequencing (NGS) in patients with high grade glioma**

Authors: Tariq Zuheir Kewan, Fahrettin Covut, Bicky Thapa, Timothy Peter Spiro, Abdo S. Haddad, Hamed Daw; Department of Medicine, Cleveland Clinic, Cleveland, OH; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH; Fairview Hospital-Cleveland Clinic, Cleveland, OH; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH

**MGMT status through the ages, literally**

Authors: Assad Ali, Anas Saeed Bamashmos, Addisson Barnett, Hong Li, Soumya Sagar, Gene H. Barnett, Lilyana Angelov, Alireza Mohammad Mohammadi, David M. Peereboom, Glen Stevens, John H. Suh, Erin Sennett Murphy, Jennifer S. Yu, Manmeet Singh Ahluwalia; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH

**Absolute lymphocyte count in patients with glioblastoma treated with temozolomide chemoradiation**

Authors: Anas Saeed Bamashmos, Assad Ali, Addisson Barnett, Soumya Sagar, Lisa A. Rybicki, Gene H. Barnett, Alireza Mohammad Mohammadi, Lilyana Angelov, Samuel T. Chao, Erin Sennett Murphy, John H. Suh, Jennifer S. Yu, David M. Peereboom, Glen Stevens, Manmeet Singh Ahluwalia; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; University Heights, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH

**Low platelet counts in patients with glioblastoma**

Authors: Anas Saeed Bamashmos, Assad Ali, Addison Barnett, Soumya Sagar, Lisa A. Rybicki, Gene H. Barnett, Alireza Mohammad Mohammadi, Lilyana Angelov, Samuel T. Chao, Erin Sennett Murphy, John H. Suh, Jennifer S. Yu, David M. Peereboom, Glen Stevens, Manmeet Singh Ahluwalia, Wei (Auston) Wei; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH
Cancer Center members indicated in BOLD

Authors: Assad Ali, Addisson Barnett, Anas Saeed Bamashmos, Hong Li, Wei (Auston) Wei, Soumya Sagar, Gene H. Barnett, Lilyana Angelov, Alireza Mohammad Mohammadi, David M. Peereboom, Glen Stevens, John H. Suh, Jennifer S. Yu, Erin Sennett Murphy, Manmeet Singh Ahluwalia; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH

(e13567) Albumin levels and Prognostic Nutritional Index in glioblastoma
Central Nervous System Tumors
Authors: Anas Saeed Bamashmos, Addison Barnett, Assad Ali, Hong Li, Lilyana Angelov, Gene H. Barnett, Alireza Mohammad Mohammadi, Samuel T. Chao, Jennifer S. Yu, Erin Sennett Murphy, John H. Suh, Glen Stevens, David M. Peereboom, Manmeet Singh Ahluwalia, Wei (Auston) Wei; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, University Heights, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH

(e13569) Impact of EGFR amplification status in newly diagnosed glioblastoma treated with Stupp protocol
Central Nervous System Tumors
Authors: Addison Barnett, Anas Saeed Bamashmos, Assad Ali, Xuefei Jia, Wei (Auston) Wei, Soumya Sagar, Gene H. Barnett, Lilyana Angelov, Alireza Mohammad Mohammadi, David M. Peereboom, Glen Stevens, John H. Suh, Erin Sennett Murphy, Jennifer S. Yu, Manmeet Singh Ahluwalia; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Burkhardt Brain Tumor NeuroOncology Center, Neurological Institute, Taussig Center Institute, Cleveland Clinic, Cleveland, OH

(e13573) Radiomics-based identification of peritumoral infiltration in de novo glioblastoma imaging presents targets amenable for potential targeted extended resection: A neurosurgical survey
Central Nervous System Tumors
Authors: Andrew E. Sloan, Gaurav Shukla, Saima Rathore, Hamed Akbari, Vinai Gondi, Christos Davatzikos; University Hospital Case Medical Center, Cleveland, OH; University of Pennsylvania, Philadelphia, PA; Center for Biomedical Image Computing and Analytics, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Proton Center, Warrenville, IL

(e14108) Major lab abnormalities as biomarkers in patients treated with immune checkpoint inhibitors: A single institution study of 1044 patients
Developmental Immunotherapy and Tumor Immunobiology
Authors: Kai Laukamp, Joseph Liput, Daniel Arnold Smith, Ariel Ann Nelson, Nikhil H. Ramaiya, Christopher J. Holmes; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; University Hospitals - Seidman Cancer Center, Cleveland, OH

(e14151) Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)
Developmental Immunotherapy and Tumor Immunobiology
Authors: Bicky Thapa, Joanna Roopkumar, Ann S Kim, Lorenzo Gervaso, Pradnya Dinkar Patil, Cassandra Calabrese, Alok A. Khorana, Pauline Funchain; Department of Medicine, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic- Taussig Cancer Institute, Cleveland, OH

ASCO Annual Meeting 2019
[23]
(e14164) Incidence and characteristics of emergency department presentations during immune checkpoint inhibitor therapy

Developmental Immunotherapy and Tumor Immunobiology
Authors: Daniel Arnold Smith, Kai Laukamp, Melanie Campbell, Robert Devita, Ariel Ann Nelson, Christopher J. Hoimes, Nikhil H. Ramaiya; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; University Hospitals - Seidman Cancer Center, Cleveland, OH

(e14191) Comprehensive analysis of lymphocyte loss kinetics in patients treated with focal fractionated radiation therapy

Developmental Immunotherapy and Tumor Immunobiology
Authors: Anirudh Yalamanchali, Jian-Yue Jin, Hong Zhang, Stuart A. Grossman, Robert F Hobbs, Susannah G. Ellsworth; Indiana University School of Medicine, Indianapolis, IN; Case Western Reserve University School of Medicine, Cleveland, OH; Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Johns Hopkins University, Baltimore, MD; Indiana University Department of Radiation Oncology, Indianapolis, IN

(e14279) Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer

Developmental Immunotherapy and Tumor Immunobiology
Authors: Weili Wang, Chen Zhang, Liang Cheng, Jianyue Jin, Feng-Ming Spring Kong; Case Western Reserve University School of Medicine, Cleveland, OH; Indiana University School of Medicine, Indianapolis, IN

(e14671) Role of ultrasound contrast agent in a tertiary cancer center: Experience in 75 patients with liver biopsy

Developmental Therapeutics and Tumor Biology (Nonimmuno)
Authors: Amir Ata Rahemaei-Azar, Elias Kikano, Daniel Arnold Smith, Nikhil H. Ramaiya, Nami R Azar; University Hospitals, Case Western Reserve University, Cleveland, OH; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA

(e14697) Feasibility and clinical impact of next-generation sequencing (NGS) in patients with stage IV or recurrent malignancies

Developmental Therapeutics and Tumor Biology (Nonimmuno)
Authors: Fahrettin Covut, Tariq Zuheir Kewan, Bicky Thapa, Abdo S. Haddad, Timothy Peter Spiro, Hamed Daw; Department of Medicine, Cleveland Clinic, Cleveland, OH; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH

(e14698) Direct oral anticoagulants (DOAC) versus warfarin and enoxaparin in ovarian vein thrombosis

Developmental Therapeutics and Tumor Biology (Nonimmuno)
Authors: Fahrettin Covut, Tariq Zuheir Kewan, Oscar Perez, Hassan Awada, Arslan Babar, Bicky Thapa, Abdo S. Haddad, Timothy Peter Spiro, Hamed Daw; Department of Medicine, Cleveland Clinic, Cleveland, OH; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH

(e15599) Development of radiotherapeutic rhenium-188 liposomes in alginate microspheres (Rhe-LAMs) for treatment of liver tumors and technetium-99m liposomes in alginate microspheres (Tech-LAMs) for image-guided treatment planning

Gastrointestinal (Noncolorectal) Cancer
Authors: Ryan D. Bitar, Jorge Lopera, Ande Bao, Jaclyn Merlo, Francisco Cigarroa, William Phillips; UT Health San Antonio, San Antonio, TX; Case Western Reserve University, Cleveland, OH

ASCO Annual Meeting 2019
[24]
(e15682) The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): Analysis of the National Cancer Database (NCDB) from 2004 to 2014
Gastrointestinal (Noncolorectal) Cancer
Authors: Aman Opneja, Gino Cioffi, Asrar Alahmadi, Nirav Patil, David Lawrence Bajor, Joel N. Saltzman, Jill Barnholtz-Sloan, Richard T. Lee; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH

(e15686) The effect of race on adherence to NCCN Guidelines for patients with biliary tract cancers (BTC) after surgery
Gastrointestinal (Noncolorectal) Cancer
Authors: Asrar Alahmadi, Gino Cioffi, Aman Opneja, Nirav Patil, David Lawrence Bajor, Joel N. Saltzman, Jill Barnholtz-Sloan, Richard T. Lee; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; The University of Texas MD Anderson Cancer Center, Houston, TX

(e15744) Microbiome signature of bile from pancreatic and biliary tract cancer patients: A pilot study
Gastrointestinal (Noncolorectal) Cancer
Authors: Shyam K. Poudel, Roshan Padmanabhan, Prabhleen Chahal, Madhusudhan Sanaka, Tyler Stevens, Kathryn Quinta, Alok A. Khorana, Davendra Sohal, Charis Eng; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH

(e16016) Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype
Genitourinary (Nonprostate) Cancer
Authors: Ariel Ann Nelson, Matthew David Wright, Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Ravi Kumar Kyasaram, Behtash Nezami, Scott Dawsey, Krupen Patel, Cheryl Eitman, Gregory MacLennan, Petros Grivas, Prateek Mendiratta, Lee Evan Ponsky, Christopher J. Hoimes; University Hospitals - Seidman Cancer Center, Cleveland, OH; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; University of Washington, Seattle, WA; University Hospitals Cleveland Medical Center, Cleveland, OH; Case Western Reserve University-Department of Pathology, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University of Washington, School of Medicine, Seattle, WA; Case Western Reserve University/University Hospitals Seidman Cancer Center, Cleveland, OH

(e16024) First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC)
Genitourinary (Nonprostate) Cancer
Authors: Archana Agarwal, Gregory Russell Pond, Ruby Gupta, Moshe Chaim Ornstein, Pedro C. Barata, Jorge A. Garcia, Alexandria Drakaki, Jae-Lyun Lee, Ravindran Kanesvaran, Mehmet Asim Bilen, Felipe R. Lorenzo, Petros Grivas, Syed A. Hussain, Catherine Curran, Guru Sonpavde; Dana Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA; McMaster University, Department of Oncology, Hamilton, ON, Canada; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH; University of California, Los Angeles, Los Angeles, CA; Asan Medical Center and University of Ulsan College of Medicine, Seoul,
Cancer Center members indicated in **BOLD**

South Korea; National Cancer Centre Singapore, Singapore, Singapore; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Univ of Utah, Salt Lake City, UT; University of Washington, School of Medicine, Seattle, WA; University of Sheffield, Academic Unit of Oncology, Department of Oncology and Metabolism, Sheffield, United Kingdom; Dana Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

**Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC)**

**Genitourinary (Nonprostate) Cancer**

Authors: Ruby Gupta, Moshe Chaim Ornstein, Anita Gul, Kimberly D Allman, Jessica Ball, Laura S. Wood, **Jorge A. Garcia**, Dendra VonMerveldt, Hans J. Hammers, **Brian I. Rini**; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Stony Brook Univ Medcl Ctr, Jackson, TN; The University of Texas Southwestern Medical Center, Dallas, TX; The University of Texas Southwestern, Dallas, TX

**Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma**

**Genitourinary (Nonprostate) Cancer**

Authors: Nirmish Singla, Oreoluwa Onabolu, Layton Woolford, Christina Stevens, Vanina Tcheuyap, Tiffani McKenzie, Qurratulain Yousuf, Yuanqing Ma, Jacob Choi, Ze Zhang, Zhiqun Xie, Tao Wang, Renee McKay, Alana Christie, Ivan Pedrosa, Christopher Przybycin, Payal Kapur, **Brian I. Rini**, James Brugarolas; University of Texas Southwestern Medical Center, Dallas, TX; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; UT Southwestern Medical Center, Dallas, TX; The University of Texas Southwestern, Dallas, TX; Cleveland Clinic Department of Pathology, Cleveland, OH

**Association of radiomic features from prostate bi-parametric MRI with Decipher risk categories to predict risk for biochemical recurrence post-prostatectomy**

**Genitourinary (Prostate) Cancer**

Authors: Lin Li, Rakesh Shiradkar, Patrick Leo, Andrei Purysko, Ahmad Alghory, **Eric A. Klein**, Cristina Magi-Galluzzi, **Anant Madabhushi**; Case Western Reserve University, Cleveland Heights, OH; Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; The University of Alabama at Birmingham, Birmingham, AL; Case Western Reserve University Case School of Engineering, Cleveland, OH

**Sonographic and histopathologic characteristics of MMR-deficient endometrial cancer**

**Gynecologic Cancer**

Authors: Daniel Arnold Smith, Raj M Paspulati, Nami R Azar, Kai Laukamp, Elias Kikano, **Stefanie Avril**, Nikhil H. Ramaiya; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

**Outcomes of post-operative treatment with concurrent systemic therapy and radiotherapy (RT) in intermediate (INT) risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration**

**Head and Neck Cancer**

Authors: Jessica Lyn Geiger, Neil McIver Woody, C. Jillian Tsai, Ahmed I. Ghanem, Neal Dunlap, Howard Liu, Brian B. Burkey, Eric Lamarre, Jamie Ku, Joseph Scharpf, Nikhil Purushottam Joshi, Jimmy J. Caudell, Farzan Siddiqui, Sandro Porceddu, Nancy Y. Lee, Shlomo A. Koyfman, **David J. Adelstein**; Cleveland Clinic, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Henry Ford Hospital/Alexandria University, Detroit, MI; University of Louisville, James Graham Brown Cancer Center, Louisville, KY; Princess Alexandra Hospital, Brisbane, Australia; All India Institute of Medical Sciences, New Delhi, India; H. Lee Moffitt Cancer Center
Cancer Center members indicated in BOLD

and Research Institute, Tampa, FL; Henry Ford Health System, Detroit, MI; School of Medicine, University of Queensland, Herston, Queensland, Australia; Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Australia

(e17570) Incidence of severe late toxicities of head and neck squamous cell cancer (HNSCC) treatment in the era of intensity modulated radiotherapy (IMRT)
Head and Neck Cancer
Authors: Akaoilisa Samuel Eziokwu, Shlomo A. Koyfman, Chandana A. Reddy, Brian Matia, Neil McIver Woody, Nikhil Purushottam Joshi, Brian B. Burkey, Joseph Scharpf, Eric Lamarre, Brandon Prendes, Robert Lorenz, Jamie Ku, David J. Adelstein, Jessica Lyn Geiger; Cleveland Clinic, Cleveland, OH

(e17590) Factors associated with recurrence and death in patients with aggressive hobnail morphology papillary thyroid carcinoma
Head and Neck Cancer
Authors: Jonathan Matthew Sharrett, Hong Li, Akeesha Shah, Christian Nasr, Joseph Scharpf, Shlomo A. Koyfman, Nikhil Joshi, Jessica Lyn Geiger; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH

(e18122) Lower survival outcomes in patients receiving an initial cancer diagnosis after presenting to the emergency department
Health Services Research, Clinical Informatics, and Quality of Care
Authors: Hannah L. Conley, Raven V. Delgado, Justin D. McCallen, Eleanor Elizabeth Harris, Andrew Wenhua Ju, Kimberly Rathbun; East Carolina University, Greenville, NC; Case Western Reserve University, Cleveland, OH

(e18170) Comparable survival of African-Americans and Caucasian patients with multiple myeloma: A hospital-based study including 117,926 patients
Health Services Research, Clinical Informatics, and Quality of Care
Authors: Ehsan Malek, Kamal Chamoun, Paolo Fabrizio Caimi, Stanton L. Gerson, Ben Kent Tomlinson, Seema Patel, Marcos J.G. De Lima, Pingfu Fu; Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH; Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Adult Malignant Hematology, Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH

(e18184) Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors
Health Services Research, Clinical Informatics, and Quality of Care
Authors: Lorenzo Gervaso, Alberto J. Montero, Xuefei Jia, Alok A. Khorana; Cleveland Clinic - Taussig Cancer Institute, Cleveland, OH; NSABP Foundation, Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Cleveland Clinic- Taussig Cancer Institute, Cleveland, OH

(e18209) Patient reported outcomes in cancer patients: Psychological, physical and functional importance
Health Services Research, Clinical Informatics, and Quality of Care

ASCO Annual Meeting 2019
[27]
Cancer Center members indicated in **BOLD**

Authors: Shiva Shrotriya, Bassam N. Estfan, Mukta Sharma, Supratik Rayamajhi, Declan Walsh; Michigan State University-Sparrow Hospital, East Lansing, MI; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Michigan State University, East Lansing, MI; Division of Internal Medicine, Michigan State University, East Lansing, MI; Harry R. Horvitz Center for Palliative Medicine, Cleveland, OH

**Swallow screen and test in cancer patients**
Health Services Research, Clinical Informatics, and Quality of Care
Authors: Shiva Shrotriya, Calvin Abro, Fawzi Abu Rous, Rosemary Trimmer, Mukta Sharma, Supratik Rayamajhi, Bassam N. Estfan, Declan Walsh; Michigan State University - Sparrow Hospital, East Lansing, MI; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Michigan State University, East Lansing, MI; Division of Internal Medicine, Michigan State University, East Lansing, MI; Harry R. Horvitz Center for Palliative Medicine, Cleveland, OH

**Admissions for neutropenic fever in myelodysplastic syndromes (MDS)**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Authors: Ambreen Fatima Ali, Aaron Thomas Gerds, Anjali S. Advani, Sudipto Mukherjee, Ronald M. Sobecks, Mikkael A. Sekeres, Betty Ky Hamilton, Babal Jha, Cameron Beau Hilton, Cassandra M. Kerr, Vera Adema, Madeline Waldron, Caitlin Siebenaller, Yasunobu Nagata, Jaroslaw P. Maciejewski, Aziz Nazha; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 9500 Euclid Ave, Cleveland, OH; Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Department of Pharmacy, Cleveland Clinic, Cleveland, OH

**Thrombotic episodes in myeloproliferative neoplasms: A population based study**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Authors: Somedeb Ball, Dhrubajyoti Bandyopadhyay, Adrija Hajra, Raktim K Ghosh, Lukman Aderoju Tijani, Abhishek Maiti; Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX; Mount Sinai St Luke's Roosevelt Hospital, New York, NY; IPGMER, Kolkata, India; Case Western Reserve University, Cleveland, OH; Texas Tech University Health Science Center, Lubbock, TX; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

**Clinical characteristics and prognosis of primary breast lymphoma: Cleveland Clinic experience**
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Authors: Tariq Zuheir Kewan, Fahrettin Covut, Bicky Thapa, Timothy Peter Spiro, Abdo S. Haddad, Hamed Daw; Department of Medicine, Cleveland Clinic, Cleveland, OH; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Fairview Hospital-Cleveland Clinic, Cleveland, OH; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH

**T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience**
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Authors: Hassan Awada, Jibran Durrani, Fahrettin Covut, Bicky Thapa, Reda Z. Mahfouz, Cassandra M. Kerr, Yasunobu Nagata, Vera Adema, Betty Ky Hamilton, Valeria Visconte, Navneet S. Majhail, Mikkael A. Sekeres, Ronald M. Sobecks, Jaroslaw P. Maciejewski; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH; Department of
Internal Medicine, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic, Cleveland, OH; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH

(e19503) Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis
Hematologic Malignancies—Plasma Cell Dyscrasia
Authors: Rajshekhar Chakraborty, Irbaz Bin Riaz, Saad Malik, Naimisha Marneni, Alex Mejia Garcia, Faiz Anwer, Alok A. Khorana, S. Vincent Rajkumar, Shaji Kumar, M. Hassan Murad, Zhen Wang, Safi U. Khan, Navneet S. Majhail; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; University of Arizona, Tuscon, AZ; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic- Taussig Cancer Institute, Cleveland, OH; West Virginia University, Morgantown, WV; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH

(e19527) Appendicular skeleton MRI in multiple myeloma: Utility and clinical implications
Hematologic Malignancies—Plasma Cell Dyscrasia
Authors: Navid Faraji, Daniel Arnold Smith, Kai Laukamp, Keval Parikh, Christos Kosmas, Nikhil H. Ramalya; University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA

(e20041) Impact of invasive regional lymph node examination (IRLNE) and time to radiation on overall survival for patients with stage I NSCLC treated with SBRT- a NCDB analysis
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Authors: Pradnya Dinkar Patil, Wei (Auston) Wei, Nathan A. Pennell; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH

(e20058) Use of surgery and stereotactic body radiotherapy (SBRT) in very elderly patients with early-stage non-small cell lung cancer (NSCLC): A national cancer database (NCDB) analysis
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Authors: Michael Kharouta, William Grubb, Tarun Kanti Podder, Tithi Biswas; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

(e20079) Radiologic imaging utilization of small cell lung cancer staging and treatment
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Authors: Elias Kikano, Thomas Bomberger, Atul B. Shinagare, Kai Laukamp, Afshin Dowlati, Nikhil H. Ramalya; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; Brigham and Women's Hospital, Boston, MA

(e20101) Defining the role of RUNX1T1 in "combined" small cell lung cancer
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Authors: Tian He, Gary Wildey, Karen McColl, Adam Kresak, Aik-Choon Tan, Afshin Dowlati; Biochemistry Department, School of Medicine, Case Western Reserve University, Cleveland, OH; University Hospital Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; University of Colorado, Aurora, CO; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

(e20663) Cross-sectional imaging utilization for EGFR, EML/ALK, and KRAS mutant non-small cell lung cancer

ASCO Annual Meeting 2019
Cancer Center members indicated in **BOLD**

**Lung Cancer—Non-Small Cell Metastatic**
Authors: Thomas Bomberger, Elias Kikano, Kai Laukamp, Daniel Arnold Smith, Amit Gupta, Kianoush Ansari-Gilani, **Afshin Dowlati**, Nikhil H. Ramaiya; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

*(e20705)* Incidence and patterns of immune related adverse events (irAEs) during chemoimmunotherapy (ChemoIO) in patients with advanced nonsquamous NSCLC

**Lung Cancer—Non-Small Cell Metastatic**
Authors: Pradnya Dinkar Patil, Alexia Zagouras, Wei (Auston) Wei, **Nathan A. Pennell**; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH

*(e20718)* Erlotinib monotherapy in the treatment of advanced non-small cell lung carcinoma: A single center experience with 187 patients from 2005-2018

**Lung Cancer—Non-Small Cell Metastatic**
Authors: Felipe Matsunaga, David Pfau, Kai Laukamp, Elias Kikano, Nikhil H. Ramaiya, **Afshin Dowlati**; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

*(e21028)* Outcomes of melanoma patients with brain metastases receiving immune checkpoint inhibitor (ICI) therapy

**Melanoma/Skin Cancers**
Authors: Fatemeh Ardeshir-Larijani, Ariel Ann Nelson, Petra Martin, Prateek Mendiratta, **Andrew E. Sloan**, Serah Choi, David B. Mansur, **Christopher J. Hoimes**; University Hospital Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals - Seidman Cancer Center, Cleveland, OH; Case Western Reserve University/University Hospitals Seidman Cancer Center, Case Western Reserve Medical Center, Cleveland, OH; University Hospital Cleveland Medical Center/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Univ Hosps Seidman Cancer Ctr, Cleveland, OH; University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

*(e21056)* Preliminary safety results of a phase II study investigating pembrolizumab in combination with postoperative intensity modulated radiotherapy (IMRT) in resected high risk cutaneous squamous cell cancer of the head and neck

**Melanoma/Skin Cancers**
Authors: Shlomo A. Koyfman, **Brian Gastman**, Allison T. Vidimos, Nikhil Purushottam Joshi, Jennifer Lucas, Christine Poblete-Lopez, Alok Vij, Jon Meine, Brian B. Burkey, Jamie Ku, Eric Lamarre, Brandon Prendes, Joseph Scharpf, Steven D Billings, Julia Samsa, Shelley Beth Robinson, **David J. Adelstein**, Jessica Lyn Geiger; Cleveland Clinic, Cleveland, OH; All India Institute of Medical Sciences, New Delhi, India; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH